Search trials – HealthDB

AI · cancer

Намерени 1,748 изпитвания за "cancer" Стр. 77 от 88

Active (not recruiting) Phase 3

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Newly Diagnosed Advanced Ovarian Cancer FIGO Stage III-IV BRCA Mutation +3

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.

Начало: 26.08.2013 Край: 29.08.2028 Възраст: 18–130 г. Treatment

Australia, Brazil, Canada +12 AstraZeneca NCT01844986

Active (not recruiting) Phase 2

Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

Newly Diagnosed Ewing Sarcoma

The purpose of this study is to find out what effects, good and/or bad, the combination of irinotecan and temozolomide has on Ewing sarcoma. Irinotecan and temozolomide are chemotherapy drugs that are used very often to treat pediatric patients at MSKCC. The investigators have used these two drugs for many years to treat patients with Ewing sarcoma whose cancer has relapsed. For patients with newly diagnosed Ewing sarcoma the current standard of care at MSKCC is a five drug chemotherapy regimen in combination with surgery and/or radiation therapy. This standard regimen is called the EFT regimen. . Some patients with Ewing sarcoma do not have their cancer cured by the chemotherapy and surgery/radiation therapy. This study adds the chemotherapy drugs called irinotecan and temozolomide to the standard EFT regimen. The investigators are trying to improve the success of standard therapy by adding these drugs. The use of irinotecan and temozolomide in this study is experimental because they have not been used before in patients with newly diagnosed Ewing sarcoma. However the investigators have found these drugs to be effective in patients with relapsed Ewing sarcoma. It is not known if adding these two drugs will improve the outcomes of patients treated for Ewing sarcoma.

Начало: 01.05.2013 Край: 01.05.2027 Възраст: 1–40 г.

United States Memorial Sloan Kettering Cancer Center NCT01864109

Active (not recruiting)

Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer

Prostate Cancer

Accelerated Hypofractionation Radiotherapy for prostate cancer of 36.25 Gy delivered in 5 fractions will not be inferior to the standard treatment of 70.2 Gy given in 26 fractions with respect to four-year biochemical failure (PSA failure) by Phoenix definition post-treatment completion.

Начало: 04.04.2013 Край: 01.02.2027 Възраст: 35–85 г. Treatment

Australia, Italy, United States University of Miami NCT01794403

Active (not recruiting)

Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®

Invasive Ductal Carcinoma Ductal Carcinoma in Situ

The purpose of this trial is to assess the safety and efficacy of the Xoft Axxent eBx System when used for single-fraction IORT in early stage breast cancer. Hypothesis: IORT using the Xoft Axxent eBx System is no worse (non-inferior) than whole breast irradiation (WBI) when used as stand-alone radiation treatment in breast conserving therapy in women with early stage breast cancer.

Начало: 08.05.2012 Край: 31.12.2029 Възраст: от 40 г. Treatment

Australia, Portugal, United States Xoft, Inc. NCT01644669

Active (not recruiting) Phase 3

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

B Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia, BCR-ABL1-Like Central Nervous System Leukemia Testicular Leukemia

This randomized phase III trial studies how well combination chemotherapy works in treating young patients with newly diagnosed B acute lymphoblastic leukemia that is likely to come back or spread, and in patients with Philadelphia chromosome (Ph)-like tyrosine kinase inhibitor (TKI) sensitive mutations. Chemotherapy drugs, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells.

Начало: 29.02.2012 Край: 03.10.2026 Възраст: 1–31 г. Treatment

Australia, Canada, Ireland +4 National Cancer Institute (NCI) NCT02883049

Active (not recruiting) Phase 2

Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET)

Metastatic Tumors

Stereotactic Ablative Radiotherapy (SABR) is a new radiation treatment that delivers high-dose, precise radiation to small tumors in 1-3 weeks of treatment. This new technique can potentially allow radiation treatments to be focused more precisely, and delivered more accurately than with older treatments. This improvement could help by reducing side effects and by improving the chance of controlling the cancer by more precisely treating the cancer. The purpose of this study is to compare SABR with current approaches of chemotherapy and conventional radiotherapy to assess the impact on overall survival and quality of life.

Начало: 01.11.2011 Край: 01.06.2026 Възраст: от 18 г. Treatment

Australia, Canada, Netherlands +1 London Health Sciences Centre Research Institute OR Law NCT01446744

Active (not recruiting) Phase 1/2

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

Neurofibromatosis 1 Neurofibromatosis Type 1 NF1 Neurofibroma, Plexiform

Background: \- Plexiform neurofibromas are tumors that grow in and around nerves. The only way to treat them is with surgery. Some of these tumors cannot be completely removed. The tumors may be too large, too numerous, or in a bad location for surgery. An experimental drug called AZD6244 hydrogen sulfate may be able to prevent the tumors from growing, slow down their growth, or shrink them. This drug has been tested in adults with cancer and in children with some types of brain cancer. This study will test how well this drug works with these types of tumors. Objectives: \- To study the safety and effectiveness of AZD6244 hydrogen sulfate in children and young adults with plexiform neurofibromas that cannot be completely removed by surgery. Eligibility: \- Children and young adults between 12 and 18 years of age who have plexiform neurofibromas that cannot be completely removed by surgery. Design: * Patients will be screened with a physical exam, medical history, blood tests, and imaging studies. * They will take the study drug twice a day with 8 ounces of water, every day for 28-day cycles of treatment. During study visits, participants will have blood and urine tests and physical exams. They will also have imaging studies to examine the tumor sizes and locations. They will answer questions about their health. They may have other tests as needed. * Participants will continue to receive the study drug as long as they have no severe side effects and the disease is not getting worse.

Начало: 21.09.2011 Край: 01.01.2032 Възраст: 2–18 г.

United States National Cancer Institute (NCI) NCT01362803

Active (not recruiting) Phase 3

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia Leukemia Cutis Myeloid Neoplasm Myeloid Sarcoma

This randomized phase III trial studies how well bortezomib and sorafenib tosylate work in treating patients with newly diagnosed acute myeloid leukemia. Bortezomib and sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib and sorafenib tosylate together with combination chemotherapy may be an effective treatment for acute myeloid leukemia.

Начало: 20.06.2011 Край: 30.09.2027 Възраст: до 29 г. Treatment

Australia, Canada, New Zealand +2 National Cancer Institute (NCI) NCT01371981

Active (not recruiting)

Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes

Genes Sporadic Chordoma

Background: Chordoma is a rare, slow growing, often fatal bone cancer derived from remnants of the embryonic notochord. It occurs mostly in the axial skeleton (skull base, vertebrae, sacrum and coccyx), is more frequent in males than females, and has a median age at diagnosis of 58.5 years, with a wide age range. This typically sporadic tumor is often advanced at presentation, and mortality is high due to local recurrence or distant metastases. The usual treatment is surgery, followed by adjuvant radiation therapy. Chemotherapy has not had a significant treatment role. Reports of a small number of families worldwide with two or more relatives with chordoma support a role for susceptibility genes in chordoma etiology. Recently we determined that duplications of the T gene co-segregated with disease in four multiplex chordoma families. The T gene encodes brachyury, a tissue-specific transcription factor that is expressed in notochord cells and is essential for formation and maintenance of the notochord. Some of the other chordoma families that we studied did not have T-gene duplications; the aggregation of chordomas in these families may result from changes in other susceptibility genes or other types of mutations targeting the T gene. We are continuing gene identification studies of multiplex chordoma families at the NIH Clinical Center under protocol 78-C-0039. We also want to determine whether alterations in any identified chordoma susceptibility genes are associated with sporadic chordoma in the general population. Objectives: The major goal of this protocol is to identify sporadic chordoma patients willing to provide germline and tumor DNA for studies to determine the frequency of alterations in chordoma susceptibility genes. Our previous protocols with SEER and Massachusetts General Hospital to identify chordoma patients were limited to residents of specific geographic regions in the U.S. (2 states and 2 metropolitan areas) or to patients with pediatric skull base tumors. This protocol will enroll patients who more broadly represent the age, site and gender distributions of sporadic chordoma in the general U.S. population. Eligibility: Eligible patients are males and females in the U.S. with chordoma diagnosed at any age and at any primary site. Because we want to obtain saliva from all participants, eligibility is limited to patients who will be greater than or equal to age 6 years at the time of enrollment. Design: The study description and contacting information including an e-mail link to the study contact person will be posted on web sites of two chordoma support groups. We will mail study information to be given to patients to colleagues at major medical centers that treat chordoma. The components of the study will be carried out in subjects' homes using materials mailed to them. Up to 100 participants will: 1) complete a self-administered Personal and Family Medical History Questionnaire, 2) collect saliva using a saliva collection kit, and 3) provide permission to obtain medical/pathology records, and paraffin blocks or slides on each primary chordoma. Parents will serve as proxies for minor children. We will recontact patients who report chordoma in at least one blood relative. If we confirm the relative's chordoma diagnosis, we will invite the study subject and selected family members to participate in clinical and gene mapping studies under protocol 78-C-0039. We may also recontact study participants to tell them about any new studies on chordoma etiology. They can decide at that time whether they want to participate in them.

Начало: 02.01.2011 Възраст: 6–99 г.

United States National Cancer Institute (NCI) NCT01200680

Active (not recruiting) Phase 3

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Acute Lymphoblastic Leukemia Adult B Lymphoblastic Lymphoma Ann Arbor Stage I B Lymphoblastic Lymphoma Ann Arbor Stage II B Lymphoblastic Lymphoma +6

This partially randomized phase III trial studies the side effects of different combinations of risk-adapted chemotherapy regimens and how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia or B-lineage lymphoblastic lymphoma that is found only in the tissue or organ where it began (localized). Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy), giving the drugs in different doses, and giving the drugs in different combinations may kill more cancer cells.

Начало: 09.08.2010 Край: 31.03.2026 Възраст: 1–30 г. Treatment

Australia, Canada, Ireland +4 Children's Oncology Group NCT01190930

Active (not recruiting) Phase 2

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Ovarian Cancer

To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian cancer.

Начало: 04.02.2010 Край: 31.12.2026 Възраст: 18–125 г. Treatment

Australia, Belgium, Canada +10 AstraZeneca NCT01081951

Active (not recruiting) Phase 1

Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery

Locally Advanced Pancreatic Adenocarcinoma Pancreatic Acinar Cell Carcinoma Pancreatic Ductal Adenocarcinoma Stage III Pancreatic Cancer AJCC v6 and v7 +1

This phase I trial studies the side effects and best dose of vaccine therapy when given together with sargramostim in treating patients with locally advanced or metastatic pancreatic cancer that cannot be removed by surgery. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood. Giving vaccine therapy directly into the tumor together with sargramostim may cause a stronger immune response and kill more tumor cells.

Начало: 01.02.2010 Край: 21.04.2027 Възраст: от 18 г.

United States National Cancer Institute (NCI) NCT00669734

Active (not recruiting)

Understanding the Psychosocial Needs of Parents Who Have Lost a Child to Cancer

Parents Who Have Lost a Child to Cancer

The purpose of this study is to understand the experiences and needs of parents who have lost a child to cancer. This will aid us in developing an intervention that may help parents cope with their loss.

Начало: 01.08.2009 Край: 02.06.2027 Възраст: от 18 г.

United States Memorial Sloan Kettering Cancer Center NCT00968500

Active (not recruiting)

Neuropsychological and Behavioral Testing in Younger Patients With Cancer

Childhood Malignant Neoplasm

This research trial studies neuropsychological (learning, remembering or thinking) and behavioral outcomes in children and adolescents with cancer by collecting information over time from a series of tests.

Начало: 27.02.2009 Възраст: от 1 г.

Australia, Canada, New Zealand +2 Children's Oncology Group NCT00772200

Active (not recruiting) Phase 2

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Neoplasm Metastasis

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.

Начало: 16.10.2008 Край: 30.04.2030 Възраст: от 18 г. Treatment

Australia, Belgium, Brazil +29 Genentech, Inc. NCT00781612

Active (not recruiting)

Study of Kidney Tumors in Younger Patients

Adult Cystic Nephroma Anaplastic Kidney Wilms Tumor Angiolipoma Cellular Congenital Mesoblastic Nephroma +21

This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.

Начало: 27.02.2006 Възраст: до 29 г.

Australia, Canada, Israel +4 Children's Oncology Group NCT00898365

Active (not recruiting)

Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Ganglioneuroblastoma Localized Resectable Neuroblastoma Localized Unresectable Neuroblastoma Regional Neuroblastoma +2

This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.

Начало: 06.11.2000 Възраст: до 30 г.

Australia, Canada, Netherlands +5 Children's Oncology Group NCT00904241

Active (not recruiting) Phase 2

An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)

Advanced non-small cell lung cancer (NSCLC)

Trial status: Authorised Overall survival (OS), Duration of response (DOR) and disease control rate (DCR) (assessed by the BICR and the investigator), Adverse events (AEs), serious adverse events (SAEs), laboratory tests, vital signs, 12-lead ECG, and physical examination, Blood drug concentration and pharmacokinetics parameters of HLX43 at different doses (ADC, total antibody, and free small molecule toxin), Positive rates of anti-HLX43 antibody (ADA) and neutralizing antibody (NAb), Potential predictive or drug resistance biomarkers, such as PD-L1 expression levels, tumor-related gene mutations or expression levels, serum proteomic profiles, Quality of life assessment, Objective response rate (ORR) (assessed by investigator as per RECIST v1.1), Progression-free survival (PFS) (assessed by the BICR and the investigator as per RECIST v1.1) Objective response rate (ORR) (assessed by the Blinded Independent Central Review [BICR] as per RECIST v1.1)

Начало: 25.03.2026 Възраст: от 18 г.

France, Italy, Poland +2 Shanghai Henlius Biotech Inc. 2025-523803-31-00

Active (not recruiting) Phase 3

Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02).

Biliary Tract Cancer

Trial status: Authorised Progression Free Survival of Rilvegostomig+Chemotherapy vs Durvalumab+Chemotherapy Overall survival of Rilvegostomig+Chemotherapy vs Durvalumab+Chemotherapy

Начало: 23.03.2026 Възраст: от 18 г.

Belgium, France, Germany +4 AstraZeneca AB 2025-523085-24-00

Active (not recruiting) Phase 3

ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Participants with Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Previously Untreated Advanced or Metastatic Gastric Gastroesophageal Junction or Esophageal Adenocarcinoma

Trial status: Authorised (Phase 2): PFS (progression-free survival) by RECIST v1.1 per investigator assessment, defined as the time between the randomization date and the date of first documented tumor progression or death from any cause (whichever occurs first), (Phase 3): Duration of response (Partial Response or Complete Response) by RECIST v1.1 per investigator assessment, defined as the time between the date of the first documentation of objective tumor response (Complete Response or Partial Response) and the date of disease progression or to death from any cause (whichever occurs first), (Phase 2): Time to response (Complete Response or Partial Response) by RECIST v1.1 per investigator assessment, defined as the time between randomization to the date of the first documentation of objective tumor response, (Phase 2): Disease control (Best overall response of confirmed Complete Response, confirmed Partial Response, or Stable Disease) by RECIST v1.1 per investigator assessment, (Phase 2): Recommended dose of pumitamig for Phase 3, (Phase 3): Objective Response by RECIST v1.1 per BICR, (Phase 3): Duration of response by RECIST v1.1 per BICR (Phase 2): ORR, to compare how two different doses of the study drug affect tumor growth to help select the better dose., (Phase 3): PFS (progression-free survival) by BICR (Blinded Independent Central Review) The ability of Pumitamig to work better than current standard treatment by assessing how long it takes before the cancer starts growing again by radiographic imaging techniques (like CT scans)., (Phase 3): OS (Overall Survival) This study will assess if people live longer when they take Pumitamig compared to other standard treatment. This is what is called "Overall Survival".

Начало: 10.03.2026 Възраст: от 18 г.

France, Germany, Italy +3 Bristol-Myers Squibb Services Unlimited Company 2025-523263-37-00

1 … 75 76 77 78 79 … 88